do risperidone and all first-generation antipsychotics reliably raise prolactin?

“resparidone itself and all the first generation antipsychotics reliably cause hyperpolectenemia”

a guest, a professor of psychiatry at Harvard Medical School said on Psychopharmacology and Psychiatry Updates, 2026-09-23, at 05:13. hear it in context →

the episode: Antipsychotics, Prolactin, and Sexual Side Effects (at 05:13). we link the show's own page; we do not re-host audio.

first, the part that holds

this one holds up. risperidone raises prolactin in most people who take it, and first-generation antipsychotics raise it as a class. the FDA labels and the trial literature both say so.

what we found when we went and looked

the FDA label for risperidone says it "elevates prolactin levels and the elevation persists during chronic administration," and that it is "associated with higher levels of prolactin elevation than other antipsychotic agents." a 2014 review in CNS Drugs reports elevated prolactin in 72–100% of people taking oral risperidone across studies, and 73.8% in the largest first-episode trial (n=555). the same review reports hyperprolactinemia in 71% of 422 people treated with first-generation drugs, and calls it "an unavoidable side effect" in most patients. the 2019 Lancet network meta-analysis found significant prolactin elevation versus placebo for both risperidone and haloperidol. the speaker's "all" is a class-level claim. it rests on shared D2-blocking pharmacology and on pooled or haloperidol-based data, not on trials of every older drug one by one.

assertion by assertion

both directions

for the speaker: risperidone's own FDA label states the effect directly, says it persists over time, and says it exceeds other antipsychotics. the haloperidol label states the same effect for antipsychotic drugs as a class. a 2014 comprehensive review reports 71% hyperprolactinemia among people on first-generation drugs and 72–100% with oral risperidone. it calls the elevation unavoidable in most patients on first-generation drugs. the 2019 Lancet network meta-analysis found significant elevation versus placebo for risperidone and haloperidol, with risperidone ranked second of all drugs studied. a 2022 review of risperidone puts the frequency at 70–91% in some samples and confirms the effect is dose-dependent.

against: "reliably" does not mean "in everyone." even in high-rate samples, a minority of people on first-generation drugs keep normal prolactin. the 2014 review notes that some tolerance can develop over long-term use, though most elevations stay above the normal limit. "all" goes further than the drug-by-drug evidence: the meta-analysis had no prolactin data for many older agents, and much of the first-generation evidence comes from haloperidol or pooled groups. finally, high prolactin on a lab test is not the same as symptoms. the review notes the literature seldom separates the two.

what this cannot say

prevalence depends on the cutoff used, the dose, sex (women show higher rates), and time on the drug, so no single percentage applies to everyone. the first-generation figure comes from a database sample, not a randomized comparison. we could not open some primary abstracts on PubMed in this session, including a widely cited 2003 point-prevalence study, so we relied on the review that summarizes them. we did not check each first-generation drug's label one by one, and we did not look at how often high prolactin causes symptoms.

sources, each one fetched and read

1. U.S. FDA, risperidone tablets prescribing information, section 5.6 Hyperprolactinemia, via openFDA drug label API What we read there: "As with other drugs that antagonize dopamine D2 receptors, risperidone tablets elevates prolactin levels and the elevation persists during chronic administration. Risperidone tablets are associated with higher levels of prolactin elevation than other antipsychotic agents." Fetched 2026-10-20 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"risperidone"&limit=1
2. U.S. FDA, haloperidol prescribing information, Precautions, set id 00bb61c8-db35-4c04-9ef7-47d447d2496b, effective 2024-11-15, via openFDA What we read there: "Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration." it also notes galactorrhea, amenorrhea, gynecomastia and impotence have been reported, and that the clinical significance is unknown for most patients. Fetched 2026-10-20 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"haloperidol"&limit=1
3. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs, 2014 What we read there: hyperprolactinemia "was found in 71% of the patients treated with FGAs" (database sample, n=422); 72–100% of people on oral risperidone had elevated prolactin, and 73.8% in a 555-person first-episode trial; "Elevated PRL values are regularly observed when FGAs are used. In most patients, such values are an unavoidable side effect." Fetched 2026-10-20 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC4022988/
4. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 2019 What we read there: olanzapine, asenapine, lurasidone, sertindole, haloperidol, amisulpride, risperidone and paliperidone were associated with significantly elevated prolactin versus placebo (mean differences 4.47–48.51 ng/mL); paliperidone and risperidone ranked highest; prolactin data were not available for many older agents. Fetched 2026-10-20 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC6891890/
5. Stojkovic M, Radmanovic B, Jovanovic M, et al. Risperidone induced hyperprolactinemia: from basic to clinical studies. Frontiers in Psychiatry, 2022 What we read there: the frequency of risperidone-induced hyperprolactinemia is ">30%" and can reach "70–91% in both sexes, with a lower incidence in men"; "prolactin levels are dose-dependent with all APs." Fetched 2026-10-20 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC9121093/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam